Inclusion Criteria:

• Must have a diagnosis of an advanced solid tumor malignancy or lymphoma (non-Hodgkin's or Hodgkin's lymphoma).
• Must have histological or cytological evidence of malignancy.
• Subjects must have an advanced malignancy, metastatic or unresectable, that has recurred or progressed following standard therapy or failed standard therapy; or for which no standard therapy currently exists, or for which they are not candidates for standard therapy. Standard therapy is defined as therapy that is approved in a particular line of therapy or considered as standard of care based on published peer reviewed data in a specific line of therapy.
• Subjects with tumors known to be responsive to gemcitabine, including those who previously received and tolerated prior gemcitabine therapy at doses of >=1000 mg/m², should only be enrolled in cohorts for which gemcitabine doses are >=1000 mg/m².
• Must be ambulatory with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Must be 18 years or older, of either sex, and of any race.
• Subjects (and/or parent/guardian for subjects who otherwise are unable to provide independent consent) must be willing to give written informed consent and able to adhere to dose and visit schedules.
• Female subjects of childbearing potential must have a negative pregnancy test within 7 days of first dose of protocol therapy.
• Female subjects of childbearing potential and male subjects whose sexual partners are of childbearing potential must agree to abstain from sexual intercourse or to use an acceptable method of contraception during the study and for 90 days following the last dose of protocol therapy. Acceptable methods of contraception include condoms (male or female) with or without spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed intrauterine device (IUD), oral or injectable hormonal contraceptive, and surgical sterilization (eg, hysterectomy or tubal ligation).
• Must have adequate bone marrow reserve as evidenced by a white blood cell (WBC) count >=3,000/ μL, absolute neutrophil count (ANC) >=1,500/μL AND platelet count >=100,000/μL.
• Must have adequate renal function as evidenced by a serum creatinine level <=1.5 x upper limit of normal (ULN) or a calculated creatinine clearance >60 mL/min.
• Subjects, except those with known Gilbert's Syndrome, must have adequate hepatic function as evidenced by a serum bilirubin level <=1.5 x the ULN AND serum levels of aspartate and alanine aminotransferase (AST/ALT) levels <=3 x the ULN for the reference lab (subjects with known hepatic metastases must have serum AST/ALT levels <=5 x the ULN for the reference lab).
• Must be recovered from the effects of any prior surgery, radiotherapy or systemic antineoplastic therapy.

Exclusion Criteria:

• Has a known hypersensitivity to SCH 900776 or gemcitabine or to any of their excipients or has received therapy with another CHK1 inhibitor.
• Has received any medication listed below more recently than the indicated washout period prior to first dose of protocol therapy or must continue to receive prohibited medications, cytochrome P450 1A2 strong inhibitors or inducers, P-gp inhibitors or inducers, any chemotherapy, or investigational drugs.
• Has persistent, unresolved Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 >=Grade 2 drug-related toxicity (except alopecia, erectile impotence, hot flashes, and decreased libido) associated with previous treatment.
• Has known human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or a known history of liver cirrhosis or active alcohol abuse.
• Is New York Heart Association (NYHA) Class III.
• Has any other medical or psychiatric condition that, in the opinion of the investigator, might interfere with the subject's participation in the trial or interfere with the interpretation of trial results.
• Has undergone major surgery within 3 weeks prior to first study drug administration after enrollment.
• Has central nervous system (CNS) or leptomeningeal metastases.
• Has received radiation therapy within 3 weeks prior to first study drug administration after enrollment or radiation therapy to >25% of bone marrow.
• Has received more than three prior chemotherapy regimens (subjects may have received prior gemcitabine if they did not experience >CTCAE v 3.0 Grade 1 myelotoxicity and after discussion with the sponsor). Subjects with more than three prior chemotherapy regimens, one or more of which were targeted, nonmyelosuppressive agents, may be considered on a case-by-case basis after discussion with the sponsor.
• Has undergone previous allogeneic or autologous stem cell transplant.
• Has had any of the following within 6 months prior to first study drug administration after enrollment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or seizure disorder.
• Has a known bleeding diathesis, eg, hemophilia.
• Has a baseline QTc interval >470 msec (ie, CTCAE v 3.0 Grade >=2).
• Currently a smoker and/or is likely to smoke during the study.
• Female subject is breast-feeding, pregnant, or intends to become pregnant.
• Participating in any other interventional clinical study. (Subject participating in another noninterventional study may be considered after discussion with the sponsor.)
• Part of the staff personnel directly related to this study.
• Family member of one of the investigational staff.